Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Congress of the Brazilian Association of Pharmaceutical Sciences/ABCF. Unidade: FCF
ABNT
WATANABE, Luis Roberto Masao et al. Indoleamine 2 3-dioxygenase (IDO) enzyme can contributes to the resistance of human melanoma naïve and resistant to BRAF inhibitor. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: http://www.ivabcfcongress.com.br/arquivos/trabalhos-cientificos.pdf. Acesso em: 15 out. 2024. , 2018APA
Watanabe, L. R. M., Oliveira, E. A. de, Sandri, S., Consolaro, M. E. L., Campa, A., & Maria-Engler, S. S. (2018). Indoleamine 2 3-dioxygenase (IDO) enzyme can contributes to the resistance of human melanoma naïve and resistant to BRAF inhibitor. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Recuperado de http://www.ivabcfcongress.com.br/arquivos/trabalhos-cientificos.pdfNLM
Watanabe LRM, Oliveira EA de, Sandri S, Consolaro MEL, Campa A, Maria-Engler SS. Indoleamine 2 3-dioxygenase (IDO) enzyme can contributes to the resistance of human melanoma naïve and resistant to BRAF inhibitor [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2018 ; 54 31 res. 221.[citado 2024 out. 15 ] Available from: http://www.ivabcfcongress.com.br/arquivos/trabalhos-cientificos.pdfVancouver
Watanabe LRM, Oliveira EA de, Sandri S, Consolaro MEL, Campa A, Maria-Engler SS. Indoleamine 2 3-dioxygenase (IDO) enzyme can contributes to the resistance of human melanoma naïve and resistant to BRAF inhibitor [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2018 ; 54 31 res. 221.[citado 2024 out. 15 ] Available from: http://www.ivabcfcongress.com.br/arquivos/trabalhos-cientificos.pdf